Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.41 |
| ▸ | JAK1 | P23458 | 8/20 | 0.41 |
| ▸ | TYK2 | P29597 | 8/20 | 0.41 |
| ▸ | JAK3 | P52333 | 8/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.34 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18088603 | 1.00 | JAK2 (0.41) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL99248 | 0.78 | JAK2 (0.35) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL100267 | 0.76 | AURKB (0.60) | JAK2JAK1TYK2JAK3AURKA | |
| SCHEMBL99168 | 0.76 | AURKB (0.60) | JAK2JAK1TYK2JAK3AURKA | |
| SCHEMBL100113 | 0.76 | AURKB (0.60) | JAK2JAK1TYK2JAK3AURKA | |
| SCHEMBL15970035 | 0.73 | CHUK (0.34) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL4088916 | 0.72 | JAK2 (0.36) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL2184103 | 0.72 | JAK2 (0.35) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL13678289 | 0.70 | ACHE (0.39) | JAK2JAK1TYK2JAK3ACHE | |
| SCHEMBL101210 | 0.69 | JAK2 (0.33) | JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662335-B2 | Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160272648-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272648-A1 | Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | JAK2 3/4885JAK1 2/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.